APOLLOMICS INC (APLM) Stock News

USA - NASDAQ:APLM - KYG0411D1236 - Common Stock

18.4331 USD

+6.25 (+51.34%)

Last: 9/17/2025, 8:23:30 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

APLM Latest News, Press Relases and Analysis

All

Press Releases

25 days ago - By: Benzinga - Mentions: USBC CURX CODX ENVB ...

12 Health Care Stocks Moving In Wednesday's Intraday Session

a month ago - By: Benzinga - Mentions: BLRX PRQR SXTC CNSP ...

12 Health Care Stocks Moving In Tuesday's After-Market Session

6 months ago - By: Apollomics Inc.

Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress

6 months ago - By: Apollomics Inc.

Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress

7 months ago - By: Apollomics Inc.

Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib

7 months ago - By: Apollomics Inc.

Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib

10 months ago - By: Apollomics Inc.

Apollomics 公布 Uproleselan 在中國治療復發或難治性急性髓系白血病患者的第 3 期銜接性試驗的主要結果

10 months ago - By: Apollomics Inc.

Apollomics 公布在中国对复发或难治性急性髓系白血病患者进行的 Uproleselan III 期桥接试验主要结果

10 months ago - By: Apollomics Inc.

Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia

10 months ago - By: Apollomics Inc.

Apollomics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

10 months ago - By: Apollomics Inc.

Apollomics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

a year ago - By: Apollomics Inc.

Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split

a year ago - By: Apollomics Inc.

Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split

a year ago - By: Apollomics Inc.

Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024

a year ago - By: Apollomics Inc.

Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

a year ago - By: Apollomics Inc.

Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

a year ago - By: Apollomics Inc.

Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress

a year ago - By: Apollomics Inc.

Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress

a year ago - By: Apollomics Inc.

Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial